Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400367 | 0.79 | PDGFRB (0.72) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL21358445 | 0.74 | PDGFRA (0.58) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL22704094 | 0.73 | PDGFRB (0.53) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL15309998 | 0.72 | SRC (0.53) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL21185626 | 0.72 | PDGFRB (0.52) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL20216770 | 0.72 | PDGFRB (0.44) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL21185438 | 0.71 | PDGFRB (0.51) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL19204448 | 0.71 | PDGFRA (0.48) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL165285 | 0.70 | PDGFRB (0.55) | PDGFRAPDGFRBSRCTGFBR1FGFR2 | |
| SCHEMBL10296329 | 0.70 | PDGFRB (0.55) | PDGFRAPDGFRBSRCTGFBR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3530654-A1 | QUINOLINYL-SUBSTITUTED CARBOXYLIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2019-08-28 | — | — | EP | disclosed |